Articles

Results 1 to 3 of 3


Troubles with Identifying Uninjured Class Members in Pay-for-delay Pharmaceutical Cases

USA - September 6 2022 When pharmaceutical manufacturers develop a new branded drug to take to market, they are granted a period of exclusivity via patent to help recoup…

Finding Uninjured Consumers In Drug Antitrust Class Actions

USA - May 16 2022 In an amicus brief filed in March opposing an appeal from end payers seeking to certify a class of end purchasers of the cholesterol drug Niaspan in…

Dr. George Korenko

Lamictal and the Myth of “Generic” “Pay-for-Delay” Cases

USA - July 24 2020 On April 22, 2020, the US Court of Appeals for the Third Circuit overturned a district court decision certifying a class of direct purchaser…

Dr. George Korenko